Amarin shares soar after FDA agrees to fast-track review of its prescription strength fish oil pill for heart patients
May 29, 2019 at 14:12 PM EDT
The FDA plans to review Vascep within six months instead of the usual 10, with a decision on approval expected sometime in late September.
